Primmune Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019

Monday, April 1, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, April 1, 2019 /PRNewswire/ -- Primmune Therapeutics today announced that it will present preclinical data

on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA. The research demonstrates
the potential of our oral TLR7 agonists to improve response rates and treatment durability.  

"There is a very strong rationale for combining agents that activate innate immunity, like TLR7 agonists, with drugs that engage adaptive immunity, like checkpoint inhibitors. This approach has the potential to address patients who inadequately respond to approved treatments," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics. "Our program builds upon historical clinical experience with TLR7 agonists, which we used to identify an ideal pharmacologic profile. We believe that long-term systemic dosing with TLR7 agonists best complements adaptive immunity approaches and we've discovered compounds that fulfill these requirements in preclinical testing."

Poster presentation details:

Title: 3262 / 12 - Discovery of a series of novel toll-like receptor 7 agonists for systemic immunotherapy of cancerPresenter: James R. Appleman, Ph.D. Session: PO.IM02.11 - Novel Immunomodulatory Agents 1Date and time: April 2, 2019 from 8:00 AM – 12:00 PM ET

About Primmune Therapeutics Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. For more information, please visit: www.primmunerx.com.

Media Contact: Cammy Duong Canale Communications Tel: 619-849-5389cammy@canalecomm.com

Cision View original content:http://www.prnewswire.com/news-releases/primmune-therapeutics-announces-presentation-at-the-american-association-for-cancer-research-aacr-annual-meeting-2019-300821509.html

SOURCE Primmune Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store